A proven connection in 1L SCLC

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small-cell lung cancer

Setting the standard of care in SCLC

TECENTRIQ was the first treatment advance in SCLC in over 20 years, showing a significant survival benefit in a hard-to-treat patient population.2

IMpower133: A Phase 3 efficacy trial in first-line ES-SCLC


A Phase 3 study in patients (n=403) with extensive-stage SCLC randomised to receive induction therapy with carboplatin and etoposide in combination with TECENTRIQ or placebo, and then TECENTRIQ or placebo maintenance therapy until disease progression or unacceptable toxicity. Primary endpoints included OS and PFS.2

  • dddd

    Significant OS benefit with 30% reduction in risk of death versus carboplatin/etoposide alone2

    A statistically significant benefit in median OS in the population treated with TECENTRIQ + carboplatin/etoposide versus carboplatin/etoposide alone (12.3 months vs 10.3 months; HR=0.70; 95% CI: 0.54, 0.91)1,2

    Carbo/etop; carboplatin/etoposide.

    Line graph to illustrate OS outcomes in the IMpower133 trial.
  • dd1


    • IMbrella A was a Phase IV, open-label, multicenter, nonrandomized, single-arm extension, and long-term observational study in patients previously enrolled in IMpower133

        • A subset of 18 patients was enrolled from the TECENTRIQ + carbo/etop arm of IMpower133

        • These patients may not be fully representative of all patients alive at the final data cutoff for IMpower133

        • Patients in the IMpower133 control arm were not eligible for enrollment in IMbrella A

    • No formal hypothesis testing was conducted, and OS data are considered exploratory


    *The 1- and 2-year overall survival (OS) rates were pre-specified secondary endpoints in IMpower133 (n=201 for the Tecentriq + CP/ET arm and n=202 for control arm), 2,4,5 the median follow-up was 35.7 months for the experimental arm and 26.4 months for the control arm (CCOD: 24 Sept 2022). The 3-, 4-, and 5-year OS rates from the exploratory merged analysis of IMpower133 and IMbrella A extension (n=18 patients who rolled over from the Tecentriq + CP/ET arm of IMpower133) were not pre-specified and are considered exploratory; the median follow-up was 59.4 months (CCOD: 16 March 2023).6


    CCOD=clinical cutoff date

  • dddd

    Significant improvement in PFS versus carboplatin/etoposide alone2

    A statistically significant improvement in PFS was also observed with TECENTRIQ + carboplatin/etoposide versus the control arm (5.2 months vs 4.3 months; HR=0.77; 95% CI: 0.62, 0.96).2

    Carbo/etop, carboplatin/etoposide.

  • dddd

    More than 50% of patients treated upfront with TECENTRIQ combination alive at 1 year2

    52% of patients treated up front with TECENTRIQ + carboplatin and etoposide were alive at 1 year vs 38% receiving carboplatin and etoposide.2

    Carbo/etop; carboplatin/etoposide.

  • dddd

    More than 30% of patients treated with TECENTRIQ combination alive at 1.5 years7

    35% of patients treated with TECENTRIQ + carboplatin and etoposide were alive at 1.5 years vs 21% receiving carboplatin and etoposide.7

    Carbo/etop; carboplatin/etoposide.
    As of data cut-off date 24th January 2019, median follow-up: 22.9 months.

TECENTRIQ: First major treatment advance for first-line ES-SCLC in over 20 years7,8

See how TECENTRIQ can help patients with lung cancer

  • References & Notes

    References & Notes

    1. TECENTRIQ (atezolizumab), Summary of Product Characteristics. 03 August 2023.


    2. Horn L, et al. N Engl J Med 2018; 379:2220-2229.


    3. Liu et al. IMpower 133LTS, ESMO 2020.


    4. Liu SV, et al. J Clin Oncol 2021;39:619-30.


    5. Liu SV, et al. Presented at ESMO Virtual Congress. 19-21 September 2020.


    6. Liu et al. Presented at World Conference on Lung Cancer; 9–12 September 2023.


    7. Sabari JK, Lok BH, Laird JH, et al. Nat Rev Clin Oncol 2017;14:549-561.


    8. Armstrong SA, Liu SV. Immune checkpoint in small cell lung cancer: a partially realized potential. Adv Ther 2019,36:1826-1832.